NO325454B1 - Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin. - Google Patents

Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin. Download PDF

Info

Publication number
NO325454B1
NO325454B1 NO20034414A NO20034414A NO325454B1 NO 325454 B1 NO325454 B1 NO 325454B1 NO 20034414 A NO20034414 A NO 20034414A NO 20034414 A NO20034414 A NO 20034414A NO 325454 B1 NO325454 B1 NO 325454B1
Authority
NO
Norway
Prior art keywords
cells
methyl
compound
acid
kit
Prior art date
Application number
NO20034414A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034414L (no
NO20034414D0 (no
Inventor
Kenichi Koike
Atsushi Komiyama
Kovichi Takeuchi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20034414D0 publication Critical patent/NO20034414D0/no
Publication of NO20034414L publication Critical patent/NO20034414L/no
Publication of NO325454B1 publication Critical patent/NO325454B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20034414A 2001-04-05 2003-10-02 Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin. NO325454B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108606.5A GB0108606D0 (en) 2001-04-05 2001-04-05 Organic compounds
PCT/US2002/010742 WO2002080925A1 (en) 2001-04-05 2002-04-05 Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders

Publications (3)

Publication Number Publication Date
NO20034414D0 NO20034414D0 (no) 2003-10-02
NO20034414L NO20034414L (no) 2003-12-04
NO325454B1 true NO325454B1 (no) 2008-05-05

Family

ID=9912339

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034414A NO325454B1 (no) 2001-04-05 2003-10-02 Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin.

Country Status (18)

Country Link
EP (1) EP1389113A1 (cs)
KR (2) KR20090034998A (cs)
CN (1) CN1529602A (cs)
AU (1) AU2002307140B2 (cs)
BR (1) BR0208663A (cs)
CA (1) CA2443092A1 (cs)
CZ (1) CZ20032705A3 (cs)
GB (1) GB0108606D0 (cs)
HU (1) HUP0303751A3 (cs)
IL (1) IL158061A0 (cs)
MX (1) MXPA03009058A (cs)
NO (1) NO325454B1 (cs)
NZ (1) NZ528934A (cs)
PL (1) PL363080A1 (cs)
RU (1) RU2304436C2 (cs)
SK (1) SK12312003A3 (cs)
WO (1) WO2002080925A1 (cs)
ZA (1) ZA200307563B (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
WO2003003006A2 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
CA2517308A1 (en) * 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
JP2008510766A (ja) * 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
CA2606716C (en) * 2005-05-02 2013-07-23 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
AU2010235334A1 (en) * 2009-04-06 2011-11-24 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing burn injuries
CN103058935B (zh) * 2013-01-15 2015-05-06 四川大学 一种嘧啶类化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

Also Published As

Publication number Publication date
GB0108606D0 (en) 2001-05-23
ZA200307563B (en) 2004-04-21
AU2002307140B2 (en) 2006-02-16
NO20034414L (no) 2003-12-04
RU2304436C2 (ru) 2007-08-20
EP1389113A1 (en) 2004-02-18
KR20040007485A (ko) 2004-01-24
WO2002080925A1 (en) 2002-10-17
KR20090034998A (ko) 2009-04-08
NZ528934A (en) 2006-10-27
RU2003130635A (ru) 2005-02-10
MXPA03009058A (es) 2004-11-22
PL363080A1 (en) 2004-11-15
IL158061A0 (en) 2004-03-28
CA2443092A1 (en) 2002-10-17
HUP0303751A3 (en) 2005-06-28
BR0208663A (pt) 2004-03-09
CN1529602A (zh) 2004-09-15
CZ20032705A3 (en) 2004-06-16
SK12312003A3 (sk) 2004-02-03
HUP0303751A2 (hu) 2005-04-28
NO20034414D0 (no) 2003-10-02

Similar Documents

Publication Publication Date Title
NO325454B1 (no) Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin.
KR20240167633A (ko) 종양 치료용 약학 조성물
JP2015522070A (ja) 消化管間質腫瘍を治療する方法
AU2002307140A1 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
US8569305B2 (en) Treatment of tuberous sclerosis associated neoplasms
CN114246864B (zh) Csf1r激酶抑制剂及其用途
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
AU2022243600A1 (en) Alk-5 inhibitors and uses thereof
KR20200102949A (ko) Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
CN116261455A (zh) 一种药物组合物及其在治疗癌症中的用途
US20120277246A1 (en) Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders
KR20210062023A (ko) Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법
JP2015536957A (ja) 肝細胞癌（ｈｃｃ）の処置のための使用のための６−オキソ−１，６−ジヒドロ−ピリダジン誘導体
ES2608585T3 (es) Derivados de pirimidilaminobenzamida para su uso en el tratamiento de una enfermedad mieloproliferativa inducida por TEL-PDGFRbeta
JP2005508846A (ja) アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用
KR101351682B1 (ko) 전신 비만세포증 치료용 조성물
US20030191131A1 (en) Use of organic compounds
AU2006200436A1 (en) Use of N-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
NZ547214A (en) Use of N-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
US20210205322A1 (en) Rictor-targeted therapy in the management of brain metastases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees